HOLON, Israel, March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada. "We are delighted to be selected to give two oral presentations at the upcoming Keystone Sy ...

HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California. "It is exciting that the progress we have made to potentially addre ...

Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Stephen Willey - Stifel Operator Ladies and gentlem ...

Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolio Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, Israel, March 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in comput ...

Compugen Reports Fourth Quarter and Full Year 2023 Results HOLON, ISRAEL, March 5, 2024 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update. Dr. Cohen-Dayag continued, "In 2023, our partner AstraZeneca continued to make progress advancing rilvegostomig, a PD-1/TIGIT bispecific antibody, the TIGIT component of which i ...

Any dividends distributed to "foreign companies", as defined in the Law, deriving from income from the Technological Enterprises will be subject, under certain conditions, including holding at least 90% of the share capital, to tax at a rate of 4%. Use of our U.S. net operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Code and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilizatio ...

Investors are always looking for stocks that are poised to beat at earnings season and Compugen Ltd. (CGEN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Compugen is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indica ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Yvonne Naughton – Head-Investor Relations and Corporate Communications Anat Cohen-Dayag – President and Chief Executive Officer Alberto Sessa – Chief Financial Officer Henry Adewoye – Chief Medical Officer Pierre Ferre – Vice President-Preclinical Development Conference Call Participants Steve Willey – Stifel Operator Ladies and gentlemen, thank you for joining us today. Welcome to CompugenÂ's Third ...

Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Stephen Willey - Stifel Financial Corp. Tony Butler - EF Hutton Ladies and gentlemen, thank you for joining us today. Welcome to CompugenÂ's Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, todayÂ's call is being recorded. An audio webcast of this call will be made avai ...